EyePoint set for record drop after experimental eye drug misses study goal

Regeneron Pharmaceuticals

17/08/2026 15:33

Updates
** Drug developer EyePoint's EYPT.O shares tumble 71% to $4.17, on track for their biggest one-day drop on record and lowest level since April 2025
** Shares of rival Ocular Therapeutix OCUL.O rise 8% to $10.79
** EYPT says experimental eye drug Duravyu missed the main goal of a late-stage trial against Regeneron's blockbuster eye drug Eylea in patients with wet age-related macular degeneration, a leading cause of vision loss
** An analysis excluding nine patients whose vision loss was unrelated to wet AMD shows Duravyu performed similarly to Eylea - EYPT
** Duravyu reduces treatment burden by 42% versus Eylea, or about two fewer injections through Week 56 - EYPT
** Says 54% patients were supplement-free through week 56, 79% received zero or one supplemental injection
** Sees data from a second late-stage wet AMD study in Q4 2026, plans potential FDA filing in H1 2027
** Including session's move, EYPT shares down ~77% YTD, while OCUL down ~11%

 (Reporting by Sahil Pandey in Bengaluru)
 ((Sahil.Pandey@thomsonreuters.com))